Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation.
To evaluate the effect of topical apraclonidine on early postoperative intraocular pressure and blood-aqueous barrier permeability, we conducted a double-masked clinical trial in which 37 patients undergoing uncomplicated phacoemulsification and posterior chamber intraocular lens implantation were randomly assigned to treatment with 1% apraclonidine or its vehicle. One drop of 1% apraclonidine or its vehicle was instilled 1/2 hour preoperatively and immediately postoperatively. In addition to intraocular pressure, aqueous flare intensity was also determined before and after the operation by using a laser flare-cell meter. In the apraclonidine group, intraocular pressure showed no significant postoperative increase, whereas it showed a significant increase at six hours in the vehicle group (P < .01). Difference between intraocular pressure recorded at the end of the operation with the Tono-Pen II and that measured postoperatively was significantly greater in the vehicle group by 3.5 to 7.0 mm Hg (P < .05 to .01). In the apraclonidine group, the aqueous flare intensity was about half that in the vehicle group with significant differences at six (P < .05) and 24 (P < .01) hours.
Araie
M
M
Department of Ophthalmology, University of Tokyo School of Medicine, Japan.
Ishi
K
K
D000316:Adrenergic alpha-Agonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000368:Aged; D001082:Aqueous Humor / Q000378:metabolism*; D001769:Blood / Q000378:metabolism*; D002387:Cataract Extraction / Q000009:adverse effects; D002463:Cell Membrane Permeability / Q000187:drug effects; D003000:Clonidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007910:Lenses, Intraocular; D008297:Male; D009798:Ocular Hypertension / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D009883:Ophthalmic Solutions
D000316:Adrenergic alpha-Agonists; D009883:Ophthalmic Solutions; C016986:apraclonidine; D003000:Clonidine